Acker, G, Greenberg, A, (1995). Angioedema induced by the angiotensin II
blocker, losartan. New England Journal of Medicine, 333, 1572.
Anderson, OK, Neldam, S, (1998). The antihypertensive effect and tolerability
of candesartan, a new generation angiotensin II antagonist, in comparison
with losartan. Blood Pressure, 7, 53-59.
Bell, TP, DeQuattro, V, Lasseter, KC, et al. (1999). Effective dose range
of candesartan cilexetil for systemic hypertension. American Journal of
Cardiology, 83, 272-275.
Black, HR, Graff, A, Shute, D, Stoltz, R, Ruff, D, Levine, J. (1997). Valsartan,
a new angiotensin antagonist for the treatment of essential hypertension:
efficacy, tolerability, and safety compared to an angiotensin converting enzyme
inhibitor, lisinopril. Journal of Human Hypertension, 11, 483-489.
Burnier, M, Brunner, HR, (2000). Angiotensin II receptor antagonists. Lancet,
355, 637-645.
Carretero, OA, Oparil, S, (2000). Essential hypertension: Part I: Definition
and etiology. Circulation, 101, 329-335.
Chan, JCN, Critchley, JAJH, Lappe, JT, et al. (1995). Randomized double blind,
parallel study of the antihypertensive efficacy and safety of losartan potassium
compared with felodipine ER in elderly patients with mild to moderate hypertension.
Journal of Human Hypertension, 9, 765-771.
Corea L, Cardoni O, Fogari R, Innocenti, P, Porcellati, C, Provvidenza, M,
Meilenbrock, S, Sullivan, J, Bodin, F, (1996).Valsartan, a new angiotensin
II antagonist for the treatment of essential hypertension: a comparative study
of the efficacy and safety against amlodipine. Clinical Pharmacologic Theories,
60, 341-46.
Cuttler, JA, (1996). High blood pressure and end-organ damage. Journal
of Hypertension, 14, S3-S6.
Dahlof B, Devereux R, DeFaire, U, et al. For the LIFE study group, (1997).
The losartan intervention for endpoint reduction (LIFE) in hypertension study:
rationale, design, and methods. American Journal of Hypertension, 10, 705-713.
Diovan. Package insert. (1997)Summit, New Jersey, Ciba-Geigy Corporation,
Pharmaceuticals Division.
Gillis J.C., Markham A.(1997). Irbesartan: a review of its pharmacodynamic
and pharmacokinetic properties and therapeutic use in the management of hypertension.
Drugs, 54, 885-902.
Goa, KL, Wagstaff, AJ.(1996).Losartan potassium: a review of its pharmacology,
clinical efficacy and tolerability in the management of hypertension. Drugs
, 51, 820-45.
Goldberg AI, Dunlay MC, Sweet CS. (1995). Safety and tolerability of losartan
potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide,
atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for
the treatment of systemic hypertension. American Journal of Cardiology
, 75, 793-95.
Gradman AH, Arcuri KE, Goldberg AI, et al.(1995). A randomized, placebo-controlled,
double-blind, parallel study of various doses of losartan potassium compared
with enalapril maleate in patients with essential hypertension. Hypertension,
25,1345-50.
Hubner, R, Hogemann, AM, Sunzel, M, (1997). Pharmacokinetics of candesartan
after single and repeated doses of candesartan cilexetil in young and elderly
healthy volunteers. Journal of Human Hypertension, 11, S19-S25.
Holwerda, NJ, Fogari, R, Angeli, P, Porcellati, C, Hereng, C, Oddou-Stock,
P, et. al. (1996). Valsartan, a new angiotensin II antagonist for the treatment
of essential hypertension: efficacy and safety compared with placebo and enalapril.
Journal of Hypertension, 14, 1147-1151.
Israili, ZH, Hall, WD. (1992) Cough and angioneurotic edema associated with
angiotensin-converting enzyme inhibitor therapy. Annals of Internal Medicine,
117, 234-242.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure (1997).The sixth report of the joint national committee
on prevention, detection, evaluation, ad treatment of high blood pressure
(JNC VI). Archives of Internal Medicine, 157, 2413-2446.
Kassler-Taub, K, Littlejohn, T, Elliott, W, Ruddy, T, Adler, E, (1998). Comparative
efficacy of two angiotensin II receptor antagonists, irbesartan and losartan,
in mild-to-moderate hypertension. American Journal of Hypertension, 11,
445-453.
Kaufman, MP, Coleridge, HM, Coleridge, JCG, Baker, DG. (1980). Bradykinin
stimulates afferent vagal C-fibers in intrapulmonary airways of dogs. American
Physiologic Society, 48, 511-517.
Luft, FC, (1998). Molecular genetics of human hypertension. Journal of
Hypertension, 16, 1871-1878.
MacKay, JH, Arcuti, KE, Goldberg, AI, Snapinn, SM, Sweet, CS.(1996). Losartan
and low-dose hydrochlorothiazide in patients with essential hypertension.
Archives of Internal Medicine, 156, 278-79.
Mallion, JM, Siche, JP, Lacourcière, Y, and the Telmisartan Blood
Pressure Monitoring Group(1999). ABPM comparison of the antihypertensive profiles
of the selective angiotensin II receptor antagonists telmisartan and losartan
in patients with mild-to-moderate hypertension. Journal of Human Hypertension
13, 657-64.
Marino, MR, Langenbacher, KM, Raymond, RH, Ford, NF, Lasseter, KC, (1998).
Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic
cirrhosis [abstract]. Journal of Clinical Pharmacology, 38, 347-356.
Mazzolai, L, Naillard, M, Rossat, J, Nussberger, J, Brenner, HR, Burnier,
M, (1999). Angiotensin II receptor blockade in normal subjects: A direct comparison
of three AT1 receptor antagonists. Hypertension, 33, 850-855.
McClellan KJ, Markham A.(1998). Telmisartan. Drugs, 56, 1039-44.
McKelvie, RS, Yusuf, S, Pericak, D, et al., (1999). Comparison of candesartan,
enalapril and their combination in congestive heart failure. Randomized Evaluation
of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation,
100, 1056-1064.
Mimran A, Ruilope L, Kerwin L, et al. (1998) A randomized, double-blind comparison
of the angiotensin II receptor antagonist, irbesartan, with the full dose
range of enalapril for the treatment of mild-to-moderate hypertension. Journal
Human Hypertension,12, 203-08.
Morice, AH, Lowry, R, Brown, MJ, Higenbottam, T, (1987). Angiotensin-converting
enzyme and the cough reflex. Lancet, 2, 1116-1118.
Oparil, S, Guthrie, R, Lewis, AJ, et al. (1998). An elective-titration study
of the comparative effectiveness of two angiotensin II-receptor blockers irbesartan
and losartan. Clinical Therapeutics,20, 398-409.
Pitt, B, Poole-Wilson, P, Segal, R., Martinez, F., Dickstein, K., Camm, JA.
(2000). Effects of losartan compared with captopril on mortality in patients
with symptomatic heart failure: randomized trial-the Losartan Heart Failure
Survival. Lancet, 355, 1582 -1587.
Sever P (1997). Candesartan cilexetil: a new, long-acting, effective angiotensin
II type 1 receptor blocker. Journal of Human Hypertension, 11, (suppl
2): S91-95.
Sica, DA, Marino, MR, Maria, R, Hammett, JL, Ferreira, I, Gehr, TW, Ford,
NF, (1997). The pharmacokinetics of irbesartan in renal failure and maintenance
hemodialysis. Clinical Pharmacology and Therapeutics, 62, 610-618.
Singer, DRJ, McGregor, GA, (1986). Angioneurotic edema associated with two
angiotensin converting enzyme inhibitors [abstract]. British Medical Journal,
293, 1243.
Stumpe, KO, Haworth, D, Hoglund, C, et al.(1998). Comparison of the angiotensin
II receptor antagonist irbesartan with atenolol for treatment of hypertension.
Blood Pressure, 7, 31-37.
Tenero, DM, Martin, DE, Miller, AK, Ilson, B, Bioke, SC, Zariffa, N, Jorkasky,
DK, (1998). Effect of age and gender on the pharmacokinetics of eprosartan.
British Journal of Clinical Pharmacology, 46, 267-270.
Timmermans, PBMWM, Wong, PC, Chiu, AT, et al. (1993). Angiotensin II receptors
and angiotensin II receptor antagonists. Pharmacology Review, 45, 205-
251.
Trenkwalder, P, Lehtovirta, M, Dahl, K, (1997). Long-term treatment with
candesartan cilexetil does not affect glucose homeostasis or serum lipid profile
in mild hypertensives with type II diabetes. Journal of Human Hypertension,
11, S81-S83.
Vachharajani, N, Shyu, WC, Smith, RA, Greene, DS (1998). The effects of age
ad gender on the pharmacokinetics of irbesartan [abstract]. British Journal
of Clinical Pharmacology, 46, 611-613.
Weber, MA, Byyny, RL, Pratt, JH, et al. (1995). Blood pressure effects of
angiotensin II receptor blocker, losartan. Archives of Internal Medicine,
155, 405-411.
